Financial Data and Key Metrics Changes - Sales grew 9% as reported and 8% in constant currency, with non-GAAP earnings per share at $2.95, up 12% year on year [9][10][21] - GAAP EPS was $2.47, with gross margin at 58.3% and adjusted operating margin at 29.1% [21][24] - Free cash flow was $159 million after funding $23 million of capital expenditures, with a net debt position of $1.1 billion at the end of the quarter [22][24] Business Line Data and Key Metrics Changes - Instruments grew mid-single digits, led by high single-digit growth in the LC and mass spec portfolio [9][10] - Recurring revenue grew 11%, driven by 9% service growth and double-digit chemistry growth [10][21] - Chemistry benefited from approximately $8 million of sales pull forward related to tariff dynamics, with overall constant currency growth rate at 7% and chemistry up 10% [11][21] Market Data and Key Metrics Changes - By end market, pharma grew low double digits, industrial grew 6%, and academic and government declined low single digits [11][17] - In the Americas, growth was partially offset by weakness in the TA division, particularly in macro-sensitive polymer and materials testing applications [10][11] - China grew high single digits, with strong performance across all end markets, particularly in pharma and CDMO segments [20][76] Company Strategy and Development Direction - The company is focused on three strategic pillars: commercial execution, revitalizing innovation, and capturing long-term growth in high-growth adjacencies [12][15] - The pending combination with BD's biosciences and diagnostic solutions business is expected to accelerate entry into high-growth adjacencies and enhance the company's growth trajectory [27][28] - The company is raising its full-year 2025 constant currency sales growth guidance to 5.5% to 7.5% and non-GAAP EPS guidance to $12.95 to $13.05 [16][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong momentum of the core business and the positive impact of the upcoming combination with BD [27][28] - The company anticipates a gradual return to growth for BD's biosciences and diagnostics solutions business, with expected growth rates improving in the coming years [31][32] - Management remains cautious about the impact of tariffs and macroeconomic conditions on certain segments, particularly in the TA division [10][71] Other Important Information - The company expects to deliver $345 million in adjusted EBITDA synergies by year five from the combination with BD, with $200 million in cost synergies and $290 million in revenue synergies [34][39] - The microbiology business from BD is seen as a strategic fit with significant value creation opportunities, particularly in infectious disease diagnostics [46][49] Q&A Session Summary Question: Can you provide an update on the replacement cycle in LC and competitive dynamics? - Management noted that the LCMS segment continues to grow high single digits, with strong replacement activity among large pharma customers and increasing growth in the CDMO customer base [57][58] Question: What is the timeline for bringing new products to market in microbiology? - Management indicated that it would take approximately three to five years to fully realize the opportunities in microbiology, with potential product introductions in two to three years [63][64] Question: How sustainable is the growth in China? - Management reported double-digit growth in China, driven by strong performance across all end markets, and remains cautiously optimistic for the back half of the year [76][78] Question: What are the drivers behind the operating margin being lighter than expected? - Management explained that the margin impact was primarily due to geographical mix and tariff remediation costs, with expectations for progressive improvement in margins in the second half of the year [82][84] Question: Can you elaborate on the $8 million sales pull forward? - Management expressed confidence in the $8 million figure based on order patterns and customer discussions, indicating it may impact both Q3 and Q4 [85][86]

Financial Data and Key Metrics Changes - The company reported sales of $771 million, reflecting a 9% increase as reported and an 8% increase in constant currency compared to the previous year [16] - Non-GAAP earnings per share (EPS) were $2.95, up 12% year on year, while GAAP EPS was $2.47 [19] - Gross margin for the quarter was 58.3%, and adjusted operating margin was 29.1%, impacted by regional sales mix and tariff surcharges [20] Business Line Data and Key Metrics Changes - Instruments grew in mid-single digits, led by high single-digit growth in the liquid chromatography (LC) and mass spectrometry (MS) portfolio [7] - Recurring revenue grew 11%, driven by 9% service growth and double-digit chemistry growth [8] - Chemistry benefited from approximately $8 million in sales pull forward related to tariff dynamics, with overall constant currency growth rate at 7% and chemistry up 10% [10] Market Data and Key Metrics Changes - By end market, pharma grew low double digits, industrial grew 6%, and academic and government declined low single digits [9][16] - In the Americas, growth was partially offset by weakness in the TA division, particularly in macro-sensitive polymer and materials testing applications [8] - Asia grew 14%, driven by double-digit growth in China, India, and Japan, while Europe grew 8% [18] Company Strategy and Development Direction - The company is focused on three strategic pillars: commercial execution, revitalizing innovation, and capturing long-term growth in high-growth adjacencies [11] - The pending combination with BD's biosciences and diagnostic solutions business is expected to accelerate entry into high-growth adjacencies and enhance the company's growth trajectory [26] - The company raised its full-year 2025 constant currency sales growth guidance to 5.5% to 7.5% and adjusted EPS guidance to $12.95 to $13.05 [15][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong momentum of the core business and the positive impact of the upcoming combination with BD [26] - The company anticipates a gradual return to growth for BD's biosciences and diagnostics solutions business, with expected growth rates of 4.5% in 2026 and 5% in 2027 [31] - Management acknowledged ongoing industry headwinds in pharma drug discovery and academic funding but remains optimistic about the overall growth potential [30][97] Other Important Information - The company plans to use free cash flow to pay down $100 million of debt and increase cash reserves in the second half of the year [22] - The company expects to deliver $345 million in adjusted EBITDA synergies from the combination with BD by year five, with $200 million in cost synergies and $290 million in revenue synergies [33][37] Q&A Session Summary Question: Can you provide an update on the replacement cycle in LC and competitive dynamics? - Management noted that the LCMS segment continues to grow high single digits, with strong replacement activity among large pharma customers and increasing growth in the CDMO customer base [55] Question: What is the timeline for bringing new products to market in microbiology? - Management indicated that it would take approximately three to five years to fully realize the opportunities in microbiology, with potential product introductions in two to three years [61] Question: How do you expect the margin to evolve in the fourth quarter? - Management expects progressive improvement in margins as volume leverage kicks in, with specific impacts from geographical mix and tariff remediation costs [80] Question: Can you elaborate on the $8 million sales pull forward? - Management expressed confidence in the $8 million figure based on order patterns and discussions with customers, indicating it may impact both Q3 and Q4 [84] Question: What is the outlook for the drug discovery business? - Management stated that the drug discovery segment remains slow, with no significant changes expected in the replacement cycle for this area [97]

Company Performance - Waters reported quarterly earnings of $2.95 per share, exceeding the Zacks Consensus Estimate of $2.93 per share, and up from $2.63 per share a year ago, representing an earnings surprise of +0.68% [1] - The company posted revenues of $771.33 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.63%, compared to $708.53 million in the same quarter last year [2] - Over the last four quarters, Waters has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - Waters shares have declined approximately 21.8% since the beginning of the year, while the S&P 500 has gained 6.1% [3] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [6] - The consensus EPS estimate for the upcoming quarter is $3.24 on revenues of $777.06 million, and for the current fiscal year, it is $12.91 on revenues of $3.11 billion [7] Industry Context - The Medical - Instruments industry, to which Waters belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Q2 2025 Financial Performance - Q2 2025 revenue reached $771 million, reflecting a 9% increase as reported and an 8% increase in constant currency[11] - Constant currency recurring revenue grew by 11%[11] - Constant currency instrument revenue grew by 4%[11] - Q2 2025 Non-GAAP EPS was $2.95, a 12% increase[11] - Waters division revenue grew by 10% in constant currency, while TA division revenue decreased by 6% in constant currency[33] Regional Performance (Constant Currency) - Asia experienced a 14% revenue growth, with China also at 14%[13] - Americas saw a 2% revenue growth[13] - Europe showed an 8% revenue growth[13] Full Year and Q3 2025 Guidance - The company projects full-year 2025 constant currency revenue growth between 5% and 7%[20] - The company projects Q3 2025 constant currency revenue growth between 4% and 7%[20] - Full-year 2025 Non-GAAP EPS is projected to be between $12.95 and $13.05[20] - Q3 2025 Non-GAAP EPS is projected to be between $3.15 and $3.25[20] Biosciences & Diagnostic Solutions Synergies - The company anticipates $200 million in cost synergies by year 3[26] - The company anticipates $290 million in revenue synergies by year 5[26]

Financial Performance - Sales for Q2 2025 were $771 million, a 9% increase from $709 million in Q2 2024[3] - GAAP EPS for Q2 2025 was $2.47, up from $2.40 in Q2 2024; non-GAAP EPS grew 12% to $2.95 from $2.63[4] - Recurring revenue increased by 11% in constant currency, with service growth at 9% and double-digit growth in chemistry[6] - Pharma sales grew 11% and Industrial sales grew 6% in constant currency; Academic & Government declined 3%[6] - Net sales for the three months ended June 28, 2025, were $771,332, an increase of 9% compared to $708,529 for the same period in 2024[22] - For the six months ended June 28, 2025, net sales reached $1,433,037, reflecting a 7% growth from $1,345,368 in the prior year[26] - Operating income for the three months ended June 28, 2025, was $188,213, slightly down from $189,112 in the same quarter of 2024[22] - Net income for the three months ended June 28, 2025, was $147,111, compared to $142,737 for the same period in 2024, marking a 3% increase[22] - The company reported a diluted net income per share of $2.47 for the three months ended June 28, 2025, up from $2.40 in the prior year[22] - Total recurring sales for the three months ended June 28, 2025, were $462,917, representing a 12% increase from $414,470 in the same period last year[24] Guidance and Projections - Full-year 2025 constant currency sales growth guidance raised to +5.5% to +7.5%[8] - Full-year 2025 non-GAAP EPS guidance raised to $12.95 to $13.05, reflecting a year-over-year growth of approximately +9% to +10%[9] - Q3 2025 constant currency sales growth expected in the range of +5.0% to +7.0%[10] - Q3 2025 non-GAAP EPS expected to be in the range of $3.15 to $3.25, indicating year-over-year growth of approximately +8% to +11%[10] - Projected sales growth rate in constant currency is estimated at 5.5% for the twelve months ended December 31, 2025, and 7.5% for the three months ended September 27, 2025[41] - The company anticipates a sales growth rate of 4.5% for the three months ended September 27, 2025, and 6.5% for the twelve months[41] Regional Performance - Sales in the Asia region for the three months ended June 28, 2025, increased by 12% to $265,940, compared to $237,431 in the same period last year[24] - The pharmaceutical market generated $461,968 in sales for the three months ended June 28, 2025, an 11% increase from $415,747 in the previous year[24] - The company experienced a 10% growth in the Waters segment for the three months ended June 28, 2025, with sales of $688,837 compared to $622,561 in the prior year[24] Expenses and Costs - Research and development expenses for the three months ended June 28, 2025, were $48,548, up from $46,182 in the same quarter of 2024[22] - The company incurred $14,284,000 in acquisition-related costs during the three months ended June 28, 2025[37] - Adjusted Non-GAAP income for the same period was $224,628,000, with a margin of 29.1%, compared to $207,084,000 and 29.2% in the prior year[37] - Operating income for the six months ended June 28, 2025, was $339,958,000, with a margin of 23.7%[37] Assets and Equity - Total assets increased to $4,718,075,000 as of June 28, 2025, up from $4,553,795,000 at the end of 2024[35] - Cash and cash equivalents rose to $367,215,000 from $325,355,000, indicating improved liquidity[35] - The company reported a total stockholders' equity of $2,159,812,000 as of June 28, 2025, up from $1,828,507,000 at the end of 2024[35] - The company’s accounts receivable stood at $730,074,000, slightly down from $733,365,000 at the end of 2024[35] Integration and Strategy - The integration planning with BD Biosciences & Diagnostic Solutions is underway, led by Chris Ross, SVP of Global Operations[5] - The company is focused on driving value creation through synergies from the combination with BD, targeting high-growth adjacencies[5] Earnings Adjustments - GAAP earnings per diluted share projected at $11.45 for the twelve months and $2.70 for the three months, with adjusted non-GAAP earnings per diluted share at $12.95 and $3.15 respectively[41] - Adjustments to earnings include $0.60 for purchased intangibles amortization and $0.53 for acquisition-related costs for the twelve months[41] - Restructuring costs and certain other items account for $0.07 in both the twelve and three-month periods[41] - ERP implementation and transformation costs are projected at $0.25 for the twelve months and $0.08 for the three months[41] - Retention bonus obligation is estimated at $0.05 for the twelve months, with no amount for the three months[41] Miscellaneous - The estimates for future gains and charges are inherently difficult to predict due to unknown timing and significance[42] - Constant currency growth rates are a non-GAAP financial measure that excludes the impact of foreign currency exchange rates[41]

Core Insights - Waters Corporation reported second quarter 2025 sales of $771 million, reflecting a 9% increase as reported and an 8% increase in constant currency compared to $709 million in the same quarter of 2024 [1][13] - The diluted earnings per share (EPS) for the second quarter of 2025 was $2.47, up from $2.40 in the second quarter of 2024, while non-GAAP EPS grew 12% to $2.95 from $2.63 [2][13] - The company is raising its full-year 2025 sales growth guidance to a range of +5.5% to +7.5% in constant currency and +5.0% to +7.0% reported [4][5] Financial Performance - The company achieved a net income of $147.1 million for the second quarter of 2025, compared to $142.7 million in the same quarter of 2024 [18] - Recurring revenue grew 11% in constant currency, with service growth at 9% and double-digit growth in chemistry [13] - The company reported operating income of $188.2 million for the second quarter of 2025, slightly down from $189.1 million in the same quarter of 2024 [17] Market and Product Insights - Instrument sales grew mid-single digits in constant currency, driven by high-single-digit growth in liquid chromatography (LC) and mass spectrometry (MS) [13] - The pharmaceutical market grew 11% in constant currency, while the industrial market grew 6%, and academic & government declined by 3% [13] - The company noted strong instrument replacement trends, particularly among large pharmaceutical and contract development and manufacturing organization (CDMO) customers [3] Guidance and Future Outlook - For the third quarter of 2025, the company expects constant currency sales growth in the range of +5.0% to +7.0% and reported sales growth of +4.5% to +6.5% [6] - Non-GAAP EPS for the third quarter of 2025 is projected to be in the range of $3.15 to $3.25, reflecting year-over-year growth of approximately +8% to +11% [6] - The company is well-positioned for future growth, particularly through its combination with BD Biosciences & Diagnostic Solutions, which is expected to enhance its strategy in high-growth adjacencies [3]

Core Viewpoint - Waters (WAT) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended June 2025, with earnings expected at $2.93 per share, reflecting an 11.4% increase, and revenues projected at $744.33 million, a 5.1% rise [1][3][18]. Earnings Expectations - The upcoming earnings report is scheduled for August 4, and the stock may rise if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4][19]. Earnings Surprise Potential - The Most Accurate Estimate for Waters is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.04%, suggesting a bullish outlook from analysts [12][19]. - A positive Earnings ESP is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 3 (Hold) [10][12]. Historical Performance - Waters has consistently beaten consensus EPS estimates in the last four quarters, with a recent surprise of +1.35% in the last reported quarter [13][14][19]. Industry Context - Waters operates within the Zacks Medical - Instruments industry, which is characterized by ongoing developments in drug discovery and development [3][18].

Core Insights - The report reveals the operational status and future dynamics of the global and Chinese High-Performance Liquid Chromatography (HPLC) market from 2025 to 2031, highlighting the profound impact of U.S. tariff policies on the HPLC industry and its development trends in the coming years [1] Industry Analysis - The report defines HPLC products and analyzes the core aspects of U.S. tariff policies, indicating that adjustments in these policies affect global supply chains and compel Chinese HPLC companies to accelerate their internationalization to address domestic market saturation and global opportunities [1] - The report predicts the global HPLC industry's scale trends over the next few years, considering optimistic, conservative, and pessimistic scenarios, and assesses the direct impacts of tariff policies on Chinese HPLC companies, including rising costs, increased market entry pressures, and supply chain restructuring challenges [1] Market Share and Competition - The report analyzes the market share of major companies in the global HPLC market, providing revenue, sales, and price data for the past three years, indicating a high market concentration where a few leading companies hold a significant portion of the market [3] - It lists the specifications, parameters, and application fields of HPLC products from major global manufacturers and evaluates the competitive landscape of the industry [3] Strategic Recommendations - The report offers several strategic recommendations for companies, including shifting from export dependence to global capacity layout, optimizing supply chain resilience, diversifying markets, innovating products and building technological barriers, compliance risk management, tariff avoidance strategies, and channel transformation and business model innovation [4] - It forecasts the future landscape of the global HPLC industry, particularly China's role in the global market, emphasizing that the HPLC market will be influenced by technological innovation, policy environment, and market demand [4] Capacity and Market Trends - The report predicts the supply and demand status and future trends of the global HPLC market, indicating steady growth in global HPLC capacity over the next few years, with major regions' market sizes expected to continue expanding [4] - It analyzes the growth potential of traditional and emerging markets, focusing on regions such as ASEAN, Russia, Eastern Europe, Mexico, Brazil, the Middle East, and North Africa [4] Product Types and Applications - The report provides a segmented analysis of the HPLC market by product types such as UVS, FD, RID, ED, and CD, noting their varying market performances, and covers application areas including pharmacies, biotechnology, CROs, academia, and chemical products [4] - It predicts future development trends for each product type and application, supported by detailed data [4] Major Manufacturers - The report lists key manufacturers in the HPLC market, including Agilent, Waters, Shimadzu, Thermo Fisher, PerkinElmer, Hitachi, Jasco, Knauer, Bekman, YoungLin, GBC, and Gilson, detailing their product specifications, market performance, and latest developments [5]

Core Viewpoint - Monteverde & Associates PC is investigating Waters Corporation regarding its merger with BD and Company's Biosciences and Diagnostic Solutions, questioning the fairness of the deal for existing shareholders [1]. Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is located in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Merger Details - Upon completion of the proposed merger, existing Waters shareholders are expected to own approximately 60.8% of the combined company [1].

Core Insights - Becton, Dickinson and Company (BDX) and Waters Corporation (WAT) have announced a strategic collaboration to merge BD's Biosciences Diagnostic Solutions business with Waters' analytical technologies expertise, creating a new entity focused on high-throughput testing in life sciences and diagnostics [1][9] Transaction Details - The merger has been unanimously approved by both companies' boards and is expected to close by the end of Q1 2026, pending regulatory and shareholder approvals [2] - BD will receive $4 billion in cash and hold a 39.2% stake in the new entity through a Reverse Morris Trust structure [8][12] Financial Projections - The combined company aims for $6.5 billion in revenues by 2025, with projections of reaching $9 billion and $3.3 billion in EBITDA by 2030 [8][11] - The total addressable market is expected to double to approximately $40 billion, allowing access to adjacent segments [10] Synergy and Growth Potential - The merger is projected to generate approximately $200 million in cost synergies by the third year post-closing and $290 million in revenue synergies by the fifth year [13] - Annualized EBITDA gains of about $345 million are anticipated by 2030, reinforcing the long-term value creation potential of the transaction [13] Market Position and Performance - BD currently has a market capitalization of $50.76 billion and an earnings yield of 8.1%, outperforming the industry average of 5.3% [5] - BDX shares have lost 21.9% year-to-date, contrasting with a 6.1% gain in the S&P 500 during the same period [3]